201 related articles for article (PubMed ID: 28347837)
1. A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain.
Wang J; Casals-Diaz L; Zurawski T; Meng J; Moriarty O; Nealon J; Edupuganti OP; Dolly O
Neuropharmacology; 2017 May; 118():223-232. PubMed ID: 28347837
[TBL] [Abstract][Full Text] [Related]
2. Botulinum Neurotoxin Chimeras Suppress Stimulation by Capsaicin of Rat Trigeminal Sensory Neurons In Vivo and In Vitro.
Antoniazzi C; Belinskaia M; Zurawski T; Kaza SK; Dolly JO; Lawrence GW
Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202143
[TBL] [Abstract][Full Text] [Related]
3. A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNFα-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons.
Nugent M; Yusef YR; Meng J; Wang J; Dolly JO
Neuropharmacology; 2018 Aug; 138():257-266. PubMed ID: 29906413
[TBL] [Abstract][Full Text] [Related]
4. NGF Enhances CGRP Release Evoked by Capsaicin from Rat Trigeminal Neurons: Differential Inhibition by SNAP-25-Cleaving Proteases.
Belinskaia M; Zurawski T; Kaza SK; Antoniazzi C; Dolly JO; Lawrence GW
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055082
[TBL] [Abstract][Full Text] [Related]
5. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential.
Meng J; Wang J; Lawrence G; Dolly JO
J Cell Sci; 2007 Aug; 120(Pt 16):2864-74. PubMed ID: 17666428
[TBL] [Abstract][Full Text] [Related]
6. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential.
Meng J; Ovsepian SV; Wang J; Pickering M; Sasse A; Aoki KR; Lawrence GW; Dolly JO
J Neurosci; 2009 Apr; 29(15):4981-92. PubMed ID: 19369567
[TBL] [Abstract][Full Text] [Related]
7. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.
Wang J; Zurawski TH; Meng J; Lawrence G; Olango WM; Finn DP; Wheeler L; Dolly JO
J Biol Chem; 2011 Feb; 286(8):6375-85. PubMed ID: 21138836
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
Dolly JO; Wang J; Zurawski TH; Meng J
FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
[TBL] [Abstract][Full Text] [Related]
9. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
10. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models.
Marinelli S; Luvisetto S; Cobianchi S; Makuch W; Obara I; Mezzaroma E; Caruso M; Straface E; Przewlocka B; Pavone F
Neuroscience; 2010 Nov; 171(1):316-28. PubMed ID: 20826198
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons.
Matak I; Rossetto O; Lacković Z
Pain; 2014 Aug; 155(8):1516-1526. PubMed ID: 24793910
[TBL] [Abstract][Full Text] [Related]
12. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
Wang J; Zurawski TH; Meng J; Lawrence GW; Aoki KR; Wheeler L; Dolly JO
FASEB J; 2012 Dec; 26(12):5035-48. PubMed ID: 22942075
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive Effects of Botulinum Toxin Type A on Trigeminal Neuropathic Pain.
Yang KY; Kim MJ; Ju JS; Park SK; Lee CG; Kim ST; Bae YC; Ahn DK
J Dent Res; 2016 Sep; 95(10):1183-90. PubMed ID: 27418174
[TBL] [Abstract][Full Text] [Related]
14. Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A.
Mustafa G; Anderson EM; Bokrand-Donatelli Y; Neubert JK; Caudle RM
Pain; 2013 Nov; 154(11):2547-2553. PubMed ID: 23933181
[TBL] [Abstract][Full Text] [Related]
15. Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain.
Zychowska M; Rojewska E; Makuch W; Luvisetto S; Pavone F; Marinelli S; Przewlocka B; Mika J
Eur J Pharmacol; 2016 Nov; 791():377-388. PubMed ID: 27619001
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X(3) inhibits the release of a pain mediator.
Ma H; Meng J; Wang J; Hearty S; Dolly JO; O'Kennedy R
Biochem J; 2014 Sep; 462(2):247-56. PubMed ID: 24844294
[TBL] [Abstract][Full Text] [Related]
17. Spinal botulinum neurotoxin B: effects on afferent transmitter release and nociceptive processing.
Huang PP; Khan I; Suhail MS; Malkmus S; Yaksh TL
PLoS One; 2011 Apr; 6(4):e19126. PubMed ID: 21559464
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of Incobotulinumtoxin A on pain, neurogenic flare and hyperalgesia in human surrogate models of neurogenic pain.
Diener SA; Breimhorst M; Vogt T; Krämer HH; Drummond PD; Geber C; Birklein F
Eur J Pain; 2017 Sep; 21(8):1326-1335. PubMed ID: 28440002
[TBL] [Abstract][Full Text] [Related]
19. Involvement of substance P in the antinociceptive effect of botulinum toxin type A: Evidence from knockout mice.
Matak I; Tékus V; Bölcskei K; Lacković Z; Helyes Z
Neuroscience; 2017 Sep; 358():137-145. PubMed ID: 28673722
[TBL] [Abstract][Full Text] [Related]
20. A back translation of pregabalin and carbamazepine against evoked and non-evoked endpoints in the rat spared nerve injury model of neuropathic pain.
Lau W; Dykstra C; Thevarkunnel S; Silenieks LB; de Lannoy IA; Lee DK; Higgins GA
Neuropharmacology; 2013 Oct; 73():204-15. PubMed ID: 23747575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
